Legal Questions Swirl Around FDA’s New Expedited Drug Program, Including Who Should Sign Off
WASHINGTON (AP) — The Food and Drug Administration commissioner’s effort to drastically shorten the review of drugs favored by President Donald Trump’s administration is causing
